Dated: October 24, 1995.

Claire V. Broome,

Deputy Administrator, Agency for Toxic Substances and Disease Registry

[FR Doc. 95–26826 Filed 10–27–95; 8:45 am]

BILLING CODE 4163–70–P

Centers for Disease Control and Prevention (CDC)

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) Announces the Following Meeting

Name: Review of the proposed protocol for the study: ''Epidemiologic Study of Adult Leukemia and Workplace Exposure to Ionizing Radiation.''

Time and Date: 9 a.m. to 4:30 p.m., November 28, 1995.

Place: Alice Hamilton Laboratory, Conference Room C, NIOSH 5555 Ridge Avenue, Cincinnati, Ohio 45213.

Status: Open to the public for observation and comment, limited only by space available.

Purpose: The purpose of this meeting is to obtain individual advice and guidance regarding the technical and scientific merits of the proposed epidemiologic study of adult leukemia and workplace exposure to ionizing radiation being conducted by NIOSH investigators. Participants will review the proposed study protocol, recommend changes based on scientific merit, and advise on the conduct of the study. Viewpoints and suggestions from industry, labor, academia, other government agencies, and the public are invited.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Thurman Wenzl, Sc.D., Research Industrial Hygienist, Health-Related Energy Research Branch, Division of Surveillance, Hazard Evaluations and Field Studies, NIOSH, 4676 Columbia Parkway, M/S R–44, Cincinnati, Ohio 45226, telephone 513/841–4490.

Dated: October 23, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–26809 Filed 10-27–95; 8:45 am]

BILLING CODE 4163–19–M

Lung Cancer and Diesel Exhaust Among Non-Metal Miners; Cohort Mortality Study With Nested Case-Control Study; Meeting

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Review of proposed protocol for the study: ''A Cohort Mortality Study with a Nested Case-control Study of Lung Cancer and Diesel Exhaust among Non-metal Miners.''

Time and Date: 9 a.m.–5 p.m., November 27, 1995.

Place: Room 503–A, Hubert H. Humphrey Building, 200 Independence Avenue, SW, Washington DC 20201.

Status: Open to the public for observation and comment, limited only by the space available. The room accommodates approximately 50 people.

Purpose: The purpose of the meeting is to obtain comment and guidance regarding the technical and scientific merits of the study: ''A Cohort Mortality Study with a Nested Case-control Study of Lung Cancer and Diesel Exhaust among Non-metal Miners,'' being conducted jointly by NIOSH and NCI.

Matters to be Discussed: Agenda items include short presentations concerning the study protocol by the study investigators, comments from the review panel members, responses and discussion of the submitted comments, and discussion open to all meeting attendees. Viewpoints and suggestions from industry, labor, academia, other government agencies, and the public are invited. Written comments will be part of the review, and should be received by the contact person listed below no later than November 13, 1995.

Contact Person for More Information: Michael D. Attfield, Ph.D., NIOSH Project Director, NIOSH, Division of Respiratory Disease Studies, (DRDS), Mailstop 234, 1095 Willowdale Road, Morgantown, West Virginia 26505–2888, telephone 304/285–5751.

Dated: October 19, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–26810 Filed 10–27–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95N–0343]

In Vitro Diagnostic Devices; Tier/Triage Management Initiative; Notice of Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public workshop to consider a tier/triage management initiative for in vitro diagnostic devices (IVD's). This management initiative is intended to improve the balance between FDA resources and workload based on a tier/triage device risk assessment. The purpose of the workshop is to obtain public comments and suggestions that will help FDA assess potential extensions and applications of the tier/triage management initiative of the Office of Device Evaluation (ODE), Center for Devices and Radiological Health (CDRH). A transcript of the meeting will be available from the Dockets Management Branch (address below).

DATES: The public workshop will be held on October 30, 1995, from 9 a.m. to 4 p.m. Submit written notices of participation as soon as possible.

ADDRESSES: The public workshop will be held at the Parklawn Building, conference rooms D and E, 5600 Fishers Lane, Rockville, MD. Submit written requests to make a presentation at the meeting, including an outline of comments, to Kaiser Aziz or Clara Sliva, FAX 301–594–5941. Submit written comments on the management initiative to the Dockets Management Branch, (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857. A transcript of the meeting will be available through the Dockets Management Branch. A limited number of overnight accommodations have been reserved at the Doubletree Hotel, Rockville, MD. Attendees requiring overnight accommodations may contact the hotel at 301–468–1100 and reference the FDA meeting group: ''GBG.'' Reservations will be confirmed at the group rate based on availability. Persons with disabilities who require special assistance to attend or participate in the workshop can be accommodated if advance notification is provided to Sociometrics, Inc., Alice Hayes, 8300 Colesville Rd., suite 550, Silver Spring, MD 20910, or FAX 301–608–3542. The availability of appropriate accommodations cannot be assured unless prior notification is provided. There is no registration fee for this meeting.

FOR FURTHER INFORMATION CONTACT: Kaiser Aziz, or Clara Sliva, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–3084, FAX 301–594–5941.

SUPPLEMENTARY INFORMATION:

Over the past few years, ODE, CDRH, has made an effort to raise the quality of the premarket review of medical devices. In the Division of Clinical Laboratory Devices (DCLD) this has resulted in a movement from a descriptive to a data driven review process with emphasis on using voluntary standards or published design or statistical methodologies as a basis for product review. One consequence of this heightened review process has been an imbalance between workload and workforce resulting in a backlog of submissions.